Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Partial Onset Seizures Clear all
Completed Phase 3 Interventional

Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures

NCT01284556
View directory record Official record
Conditions
Epilepsy
Interventions
Phenobarbital, Placebo tablet
Drug
Lead sponsor
West-Ward Pharmaceutical
Industry
Eligibility
17 Years to 70 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

NCT01728077
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
16 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Jul 21, 2026, 5:52 PM EDT
Withdrawn Phase 2 Interventional

Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy

NCT00982787
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Botanical extract from Passiflora incarnata
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

NCT00235755
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

NCT01964560
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Orlando, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Jul 21, 2026, 5:52 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Eslicarbazepine Acetate Monotherapy Long Term Study

NCT00910247
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
96
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

NCT01261325
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 80 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

NCT00152503
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (UCB44212)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699582
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

NCT00419393
View directory record Official record
Conditions
Epilepsy
Interventions
Keppra XR (Levetiracetam XR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Dothan, Alabama • Northport, Alabama • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Results available

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

NCT00955357
View directory record Official record
Conditions
Partial Epilepsies
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
17 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
40
States / cities
Irvine, California • Rancho Mirage, California • Clearwater, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

NCT01243177
View directory record Official record
Conditions
Epilepsy, Monotherapy
Interventions
Lacosamide, Carbamazepine-Controlled Release
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
16 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655486
View directory record Official record
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

NCT02072824
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 3 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Orlando, Florida • Tampa, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jul 21, 2026, 5:52 PM EDT
Terminated Phase 3 Interventional Results available

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

NCT01668654
View directory record Official record
Conditions
Epilepsy
Interventions
retigabine/ezogabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 29 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

NCT00175890
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Levetiracetam, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 4 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

NCT01142193
View directory record Official record
Conditions
Epilepsy
Interventions
USL255, Placebo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Phoenix, Arizona • Ventura, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655551
View directory record Official record
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

NCT00772603
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Placebo, 2400mg SPN-804, 1200mg SPN-804
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Jul 21, 2026, 5:52 PM EDT
Terminated Phase 4 Interventional Results available

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

NCT01607346
View directory record Official record
Conditions
Epilepsy
Interventions
ezogabine/retigabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Bethesda, Maryland • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Jul 21, 2026, 5:52 PM EDT
Terminated Phase 3 Interventional Results available

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

NCT02519439
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Santa Monica, California • Lexington, Kentucky • Golden Valley, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129
View directory record Official record
Conditions
Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
4 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Jul 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Open-label Extension to Protocol 1042-0600

NCT00512317
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jul 21, 2026, 5:52 PM EDT